Back to Agenda
Session 6: IMPD-Q Only Trials : Operational and Disclosure Aspects
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
Ruediger Pankow, DRSC
Clinical Trial Regulatory Consultant | CTIS SME, Independent Consultant, Germany
Session 6: IMPD-Q Only Trials : Operational and Disclosure Aspects
Speaker(s)
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
Opening: Why does IMPD-Q only application exists?
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
IMPD-Q Owner Experience
Raquel Vaquer Pérez
EU CTR implementation lead, Bristol-Myers Squibb, Belgium
IMPD-Q Owner Experience
Stéphanie Kromar
Senior Regulatory Affairs Manager, European Organisation for Research and Treatment of Cancer (EORTC) , Belgium
Academia Perspective
Jan Willem Kleinovink
Scientific staff / Validation team lead / CTIS Support, Central Committee on Research Involving Human Subjects (CCMO), Netherlands
Member State Experience
Marianne Lunzer, DrMed
Assessor, Dept of Clinical Trials, Federal Office for Safety in Health Care, AGES, Austria
Contributing Panelist
Have an account?